Frans J.M. van Breukelen , Karin Mattson , Giuseppe Giaccone , Nico van Zandwijk , Hans T. Planteydt , Anne Kirkpatrick , Otilia Dalesio
{"title":"米托蒽醌治疗恶性胸膜间皮瘤:EORTC肺癌合作组的研究","authors":"Frans J.M. van Breukelen , Karin Mattson , Giuseppe Giaccone , Nico van Zandwijk , Hans T. Planteydt , Anne Kirkpatrick , Otilia Dalesio","doi":"10.1016/0277-5379(91)90430-L","DOIUrl":null,"url":null,"abstract":"<div><p>46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m<sup>2</sup> every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 12","pages":"Pages 1627-1629"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90430-L","citationCount":"46","resultStr":"{\"title\":\"Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC lung cancer cooperative group\",\"authors\":\"Frans J.M. van Breukelen , Karin Mattson , Giuseppe Giaccone , Nico van Zandwijk , Hans T. Planteydt , Anne Kirkpatrick , Otilia Dalesio\",\"doi\":\"10.1016/0277-5379(91)90430-L\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m<sup>2</sup> every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":\"27 12\",\"pages\":\"Pages 1627-1629\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90430-L\",\"citationCount\":\"46\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/027753799190430L\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190430L","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC lung cancer cooperative group
46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
